<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2019-34-1-124-129</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-691</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>ТРОМБОЦИТЫ, АСПАРТАТАМИНОТРАНСФЕРАЗА, ФАКТОР НЕКРОЗА ОПУХОЛИ-α — ЛАБОРАТОРНАЯ ПАНЕЛЬ ДИАГНОСТИКИ СТАДИИ ФИБРОЗА ПЕЧЕНИ</article-title><trans-title-group xml:lang="en"><trans-title>PLATELETS, ASPARTATE AMINOTRANSFERASE, TUMOR NECROSIS FACTOR-α: LABORATORY PANEL FOR DIAGNOSIS OF LIVER FIBROSIS STAGE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щекотова</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchekotova</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующая кафедрой клинической лабораторной диагностики факультета дополнительного профессионального образования,</p><p>614000, Пермь, ул. Петропавловская, 26</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Head of the Department of Clinical Laboratory Diagnostics Faculty, Faculty of Continuous Medical Education,</p><p>26, Petropavlovskaya str., Perm, 614000</p></bio><email xlink:type="simple">al_shchekotova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Булатова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bulatova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующая кафедрой клинической лабораторной диагностики факультета дополнительного профессионального образования,</p><p>614000, Пермь, ул. Петропавловская, 26</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor of the Department of Clinical Laboratory Diagnostics Faculty, Faculty of Continuous Medical Education,</p><p>26, Petropavlovskaya str., Perm, 614000</p></bio><email xlink:type="simple">al_shchekotova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соснин</surname><given-names>Д. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Sosnin</surname><given-names>D. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор кафедры клинической лабораторной диагностики факультета дополнительного профессионального образования,</p><p>614000, Пермь, ул. Петропавловская, 26</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor of the Department of Clinical Laboratory Diagnostics Faculty, Faculty of Continuous Medical Education, </p><p>26, Petropavlovskaya str., Perm, 614000</p></bio><email xlink:type="simple">sosnin_dm@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Третьякова</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Tretyakova</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, доцент кафедры поликлинической терапии,</p><p>614000, Пермь, ул. Петропавловская, 26</p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), Associate Professor of the Department of Policlinic Therapy,</p><p>26, Petropavlovskaya str., Perm, 614000</p></bio><email xlink:type="simple">tretyakovayi@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пермский государственный медицинский университет имени академика Е.А. Вагнера Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm State Medical University named after Academician E. A. Wagner</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>22</day><month>04</month><year>2019</year></pub-date><volume>34</volume><issue>1</issue><fpage>124</fpage><lpage>129</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Щекотова А.П., Булатова И.А., Соснин Д.Ю., Третьякова Ю.И., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Щекотова А.П., Булатова И.А., Соснин Д.Ю., Третьякова Ю.И.</copyright-holder><copyright-holder xml:lang="en">Shchekotova A.P., Bulatova I.A., Sosnin D.Y., Tretyakova Y.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/691">https://www.sibjcem.ru/jour/article/view/691</self-uri><abstract><sec><title>Цель</title><p>Цель: оценить возможности количества тромбоцитов, активности аспартатаминотрансферазы (АСТ) и концентрации фактора некроза опухоли-α (ФНО-α) для оценки выраженности фиброза печени при хроническом гепатите С (ХГС), разработать формулу подсчета индекса фиброза (ИФ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование были включены 70 пациентов с ХГС и 30 практически здоровых лиц. Плотность печени определяли методом ультразвуковой эластографии (УЗЭ).</p></sec><sec><title>Результаты</title><p>Результаты. При проведении корреляционного анализа выявлены сильные взаимосвязи между стадией фиброза по данным УЗЭ и количеством тромбоцитов (r=0,83), АСТ (r=0,83) и ФНО-α (r=0,81). Выявлены оптимальные точки разделения лабораторных тестов для исключения фиброза: количество тромбоцитов более 270×109 /л (чувствительность теста 96,2%), активность АСТ менее 44 Е/л (чувствительность 96,2%), концентрация ФНО-α ниже 1,9 пг/мл (чувствительность 92,3%). Полученные значения лабораторных показателей использовали для расчета ИФ печени. Значение ИФ в интервале от 0 до 0,5 свидетельствует об отсутствии фиброза (стадия F0), значение ИФ в интервале от 0,6 до 2,5 соответствует умеренной стадии фиброза (F1-2), значение ИФ более 2,5 соответствует выраженному фиброзу/циррозу печени (F3-4) с диагностической чувствительностью 83% и специфичностью 78%.</p></sec><sec><title>Заключение</title><p>Заключение. Количество тромбоцитов, активность АСТ, концентрация ФНО-α и ИФ с включением данных лабораторных тестов могут использоваться для исключения фиброза у пациентов с ХГС и стратификации стадий фиброза печени (ФП).</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study significance of platelet count and values of aspartate aminotransferase and tumor necrosis factor-α in the evaluation of the severity of liver fibrosis in chronic hepatitis C and for the development of fibrosis index calculation formula.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. The study included 70 patients with chronic hepatitis C end 30 healthy persons. Liver density was estimated by ultrasound elastography.</p></sec><sec><title>Results</title><p>Results. The correlation analysis revealed strong relationships between the ultrasound elastography findings of fibrosis stage and the platelet count (r=0.83), aspartate aminotransferase (r=0.83), and tumor necrosis factor-α (r=0.81). The optimal separation points of laboratory tests for fibrosis exclusion were identified as follows: platelet count&gt;270×109 /L (test sensitivity=96.2%), aspartate aminotransferase level&lt;44 E/L (sensitivity=96.2%), and tumor necrosis factor-α concentration below 1.9 pg/mL (sensitivity=92.3%). The obtained values of laboratory parameters were used for calculation of the liver fibrosis index. The value of the fibrosis index ranging between 0 and 0.5 indicated the absence of fibrosis (stage F0), the value of the fibrosis index ranging between 0.6 and 2.5 corresponded to the moderate stage of fibrosis (F1-2), and the value of the fibrosis index&gt;2.5 corresponded to the severe fibrosis/cirrhosis of the liver (F3-4) with diagnostic sensitivity of 83% and specificity of 78%.</p></sec><sec><title>Conclusion</title><p>Conclusion. Platelet count, the values of aspartate aminotransferase and tumor necrosis factor-α levels, fibrosis index, and laboratory test data can be used for ruling out fibrosis in chronic hepatitis C patients as well as for stratification of liver fibrosis stages.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический гепатит С</kwd><kwd>фиброз печени</kwd><kwd>тромбоциты</kwd><kwd>аспартатаминотрансфераза</kwd><kwd>фактор некроза опухоли-α</kwd><kwd>индекс фиброза</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic hepatitis C</kwd><kwd>liver fibrosis</kwd><kwd>platelets</kwd><kwd>aspartate aminotransferase</kwd><kwd>tumor necrosis factor-α</kwd><kwd>fibrosis index</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wynn А. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008; 214(2):199–210. https://doi:10.1002 /path.2277.</mixed-citation><mixed-citation xml:lang="en">Wynn А. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008; 214(2): 199–210. doi: 10.1002/path.2277.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Saffioti F., Pinzani M. Development and Regression of Cirrhosis. Dig Dis. 2016;34(4):374–381. https://doi: 10.1159/000444550</mixed-citation><mixed-citation xml:lang="en">Saffioti F., Pinzani M. Development and Regression of Cirrhosis. Dig Dis. 2016;34(4):374–381. https://doi: 10.1159/000444550</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Baranova A., Lal P., Birerdinc A., Younossi Z.M. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. DOI: 10.1186/1471- 230x-11-91.</mixed-citation><mixed-citation xml:lang="en">Baranova A., Lal P., Birerdinc A., Younossi Z.M. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. https://doi: 10.1186/1471-230x-11-91</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sandrin L., Fourquet B., Hasquenoph J.M., Yon S., Fournier C., Mal F. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–1713. http://dx.doi.org/10.1016/j.ultrasmedbio.2003.07.001.</mixed-citation><mixed-citation xml:lang="en">Sandrin L., Fourquet B., Hasquenoph J.M., Yon S., Fournier C., Mal F. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. 2003;29:1705–1713. http://dx.doi.org/10.1016/j.ultrasmedbio.2003.07.001.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann. Intern. Med. 2013;158:807–820. DOI: 10.7326/0003-4819-158-11-201306040-00005.</mixed-citation><mixed-citation xml:lang="en">Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann. Intern. Med. 2013;158:807–820. DOI: 10.7326/0003-4819-158-11-201306040-00005.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Щекотова А.П., Булатова И.А., Ройтман А.П. Чувствительность и специфичность определения гиалуроновой кислоты, коэффициента де Ритиса и ВЭФР для диагностики ХГ и ЦП. Пермский медицинский журнал. 2013;4(30):84–89.</mixed-citation><mixed-citation xml:lang="en">Shchyokotova A.P., Bulatova I.A., Rojtman A.P. Chuvstvitel’nost’ i specifichnost’ opredeleniya gialuronovoj kisloty, koehfficienta de Ritisa i VEFR dlya diagnostiki HG i CP. Permskij medicinskij zhurnal. 2013;4(30):84–89 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert-Bismut F., et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40–51. DOI: 10.1186/1471-230x-7-40.</mixed-citation><mixed-citation xml:lang="en">Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert-Bismut F., et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40–51. DOI: 10.1186/1471- 230x-7-40.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Williams A.L., Hoofnagle J.H. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterol. 1988;95(3):734–739.</mixed-citation><mixed-citation xml:lang="en">Williams A.L., Hoofnagle J.H. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterol. 1988;95(3):734–739.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pinzani M., Rombouts К., Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J. Hepatol. 2005;42:22–36.</mixed-citation><mixed-citation xml:lang="en">Pinzani M., Rombouts К., Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J. Hepatol. 2005;42:22–36.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Булатова И.А. Фиброз при хронических заболеваниях печени: механизмы развития, клинико-лабораторная оценка прогрессирования и мониторинг терапии. Автореф. дис. …. д-ра мед. наук. Пермь; 2016:50.</mixed-citation><mixed-citation xml:lang="en">Bulatova I.A. Fibroz pri hronicheskih zabolevaniyah pecheni: mekhanizmy razvitiya, kliniko-laboratornaya ocenka progressirovaniya i monitoring terapii. Avtoref dis. … dokt. med. nauk. Perm’; 2016:50 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Левитан Б.Н., Астахин А.В., Левитан Г.Б. Фактор некроза опухоли и его растворимые рецепторы при хронических гепатитах и циррозах печени. Экспериментальная и клиническая гастроэнтерология. 2017;2(138):62–66.</mixed-citation><mixed-citation xml:lang="en">Levitan B.N., Astahin A.V., Levitan G.B. Faktor nekroza opuholi i ego rastvorimye receptory pri hronicheskih gepatitah i cirrozah pecheni. Ehksperimental’naya i klinicheskaya gastroehnterologiya. 2017;2(138):62–66 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Z.H., Xin Y.N., Dong Q.J., Wang Q., Jiang X.J., Zhan S.H., et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. J. Hepatol. 2011;53:726–736.</mixed-citation><mixed-citation xml:lang="en">Lin Z.H., Xin Y.N., Dong Q.J., Wang Q., Jiang X.J., Zhan S.H., et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. J. Hepatol. 2011;53:726–736.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sebastiani G., Vario A., Guido M. Noninvasive assessment of liver fibrosis. Ann. Gastroenterol. 2012;3(25):218–231.</mixed-citation><mixed-citation xml:lang="en">Sebastiani G., Vario A., Guido M. Noninvasive assessment of liver fibrosis. Ann. Gastroenterol. 2012;3(25):218–231.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
